Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis

Bibliography

• Furmark T. Social phobia: overview of community surveys. Acta Psychiat Scand 2002;105(2):84-93
   PubMed Web of Science ®Google Scholar
• Katzelnick DJ, Kobak KA, DeLeire T, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiat 2001;158(12):1999-2007
   PubMed Web of Science ®Google Scholar
• Kushnir J, Marom S, Mazar M, et al. The link between social anxiety disorder, treatment outcome, and sleep difficulties among patients receiving cognitive behavioral group therapy. Sleep Med 2014;15(5):515-21
   PubMed Web of Science ®Google Scholar
• Schneier FR, Foose TE, Hasin DS, et al. Social anxiety disorder and alcohol use disorder co-morbidity in the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2010;40(06):977-88
   Google Scholar
• DeWit DJ, Ogborne A, Offord DR, et al. Antecedents of the risk of recovery from DSM-III-R social phobia. Psychol Med 1999;29(03):569-82
   Google Scholar
• Yoshinaga N, Niitsu T, Hanaoka H, et al. Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting: a randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment. BMJ Open 2013;3:2
   Google Scholar
• Swinson RP. Management of anxiety disorders. Can J Psychiatry 2006;51:1S-92S
   Web of Science ®Google Scholar
• Tollefson GD, Rosenbaum JF. Selective serotonin reuptake inhibitors. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. 2nd edition. American Psychiatric Press; Washington, DC, USA: 1998
   Google Scholar
• Blanco C, Schneier FR, Schmidt A, et al. Pharmacological treatment of social anxiety disorder: a meta analysis. Depress Anxiety 2003;18(1):29-40
   PubMed Web of Science ®Google Scholar
• Gould RA, Buckminster S, Pollack MH, et al. Cognitive behavioral and pharmacological treatment for social phobia: a meta analysis. Clin Psychol-Sci PR 1997;4(4):291-306
   Web of Science ®Google Scholar
• Barker MJ, Greenwood KM, Jackson M. Cognitive effects of long-term benzodiazepine use. CNS Drugs 2004;18(1):37-48
   PubMed Web of Science ®Google Scholar
• Rosenthal R. Meta-analytic procedures for social research. Sage; Thousand Oaks, CA, USA: 1991
   Google Scholar
• Borenstein M, Rothstein H. Comprehensive meta-analysis: a computer program for research synthesis. Biostat Inc; Englewood, NJ, USA: 1999
   Google Scholar
• Rosenthal R. The “file drawer problem” and tolerance for null results. Psychol Bull 1979;85:638-41
   Google Scholar
• Orwin RG. A fail-safe N for effect size in meta-analysis. J Educ Stat 1983;8(2):157-9
   Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088-101
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. Trim and fill: a simple funnel plot–based method of testing and adjusting for publication bias in meta analysis. Biometrics 2000;56(2):455-63
   PubMed Web of Science ®Google Scholar
• Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiat 1991;48(10):938-45
   Google Scholar
• Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12 week outcome. Arch Gen Psychiat 1998;55:1133-41
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Sawyer AT, Korte KJ, et al. Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? A meta-analytic review. Int J Cogn Ther 2009;2(2):160
   Google Scholar
• Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiat 2006;63(3):298-304
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Wu JQ, Boettcher H. D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol Mood Anxiety Disord 2013;3:11-1-10
   PubMedGoogle Scholar
• Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiat 2008;63(6):544-9
   PubMed Web of Science ®Google Scholar
• Smits JA, Rosenfield D, Otto MW, et al. D-Cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiat 2013;73(11):1054-8
   PubMed Web of Science ®Google Scholar
• Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 1999;100(3):193-8
   PubMed Web of Science ®Google Scholar
• Hofmann SG. D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse. Depress Anxiety 2014;31:175-7
   PubMed Web of Science ®Google Scholar
• Smits JAJ, Rosenfield D, Otto MW, et al. D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiat Res 2013;47:1455-81
   PubMed Web of Science ®Google Scholar
• Allgulander C, Mangano R, Zhang J, et al. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharm Clin 2004;19(6):387-96
   PubMed Web of Science ®Google Scholar
• Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychop 2007;10(2):263-74
   PubMed Web of Science ®Google Scholar
• Baldwin D, Bobes J, Stein D, et al. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 1999;175(2):120-6
   PubMed Web of Science ®Google Scholar
• Barnett SD, Kramer ML, Casat CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002;16(4):365-8
   PubMed Web of Science ®Google Scholar
• Blanco C, Heimberg R, Schneier F, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010;67(3):286-95
   PubMed Web of Science ®Google Scholar
• Blomhoff S, Haug T, Hellström K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001;179(1):23-30
   PubMed Web of Science ®Google Scholar
• Clark D, Ehlers A, Mcmanus F, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003;71(6):1058
   PubMed Web of Science ®Google Scholar
• Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13(6):423-8
   PubMed Web of Science ®Google Scholar
• Davidson J, Foa E, Huppert J, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiat 2004;61(10):1005-13
   PubMed Web of Science ®Google Scholar
• Furmark T, Appel L, Michelgåard A, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiat 2005;58(2):132-42
   PubMed Web of Science ®Google Scholar
• Heimberg R, Liebowitz M, Hope D, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998;55(12):1133-41
   PubMed Web of Science ®Google Scholar
• Kasper S, Stein D, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder Randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005;186(3):222-6
   PubMed Web of Science ®Google Scholar
• Katzelnick D, Kobak K, Greist J, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152(9):1368-71
   PubMed Web of Science ®Google Scholar
• Kobak K, Greist J, Jefferson J, Katzelnick D. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 2002;22(3):257-62
   PubMed Web of Science ®Google Scholar
• Kobak KA, Taylor LV, Warner G, et al. St John’s wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol 2005;25(1):51-8
   PubMed Web of Science ®Google Scholar
• Lader M, Stender K, Bürger V, Nil R. Efficacy and tolerability of escitalopram in 12-and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004;19(4):241-8
   PubMed Web of Science ®Google Scholar
• Lepola U, Bergtholdt B, St Lambert J, et al. Controlled-release paroxetine in the treatment of patietns with social anxiety disorder. J Clin Psychiat 2004;65(2):222-9
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992;49(4):290-300
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Stein M, Tancer M, et al. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in treatment of generalized social anxiety disorder. J Clin Psychiatry 2002;63(1):66-74
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Demartinis N, Weihs K, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 2003;64(7):785-92
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Gelenberg A, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005a;62(2):190-8
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalzed social anxiety disorder. J Clin Psychiat 2005b;66:238-47
   PubMed Web of Science ®Google Scholar
• Lott M, Greist JH, Jefferson JW, et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 1997;17(4):255-60
   PubMed Web of Science ®Google Scholar
• Noyes R, Moroz G, Davidson J, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 1997;17(4):247-54
   PubMed Web of Science ®Google Scholar
• Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19(4):341-8
   PubMed Web of Science ®Google Scholar
• Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004;24(2):141-9
   PubMed Web of Science ®Google Scholar
• Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 2004;24(5):488-96
   PubMed Web of Science ®Google Scholar
• Schneier F, Goetz D, Campeas R, et al. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998;172(1):70-7
   PubMed Web of Science ®Google Scholar
• Schutters SI, Van Megen HJ, Van Veen JF, et al. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2010;25(5):302-4
   PubMed Web of Science ®Google Scholar
• Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder). JAMA 1998;280(8):708-13
   PubMed Web of Science ®Google Scholar
• Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiat 1999;156(5):756-60
   PubMed Web of Science ®Google Scholar
• Stein D, Cameron A, Amrein R, et al. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol 2002;17(4):161-70
   PubMed Web of Science ®Google Scholar
• Stein MB, Pollack MH, Bystritsky A, et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 2005;177(3):280-8
   PubMed Web of Science ®Google Scholar
• The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997;247(2):71-80
   Google Scholar
• Van Ameringen M, Lane R, Walker J, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001;158(2):275-81
   PubMed Web of Science ®Google Scholar
• Versiani M, Nardi AE, Mundim FD, et al. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Brit J Psychiat 1992;161(3):353-60
   PubMed Web of Science ®Google Scholar
• Westenberg H, Stein D, Yang H, et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004;24(1):49-55
   PubMed Web of Science ®Google Scholar
• Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol 2005;19(5):551-3
   PubMed Web of Science ®Google Scholar